# Health Canada Approves Lilly’s Mounjaro for Cardiovascular Risk Reduction

By Riza Dagoc

Canonical URL: https://www.tokenpost.com/news/regulation/60796
Published: 2026-11-18T20:14:24.000Z
Updated: 2026-11-18T20:14:24.000Z
Section: Regulation

> The indication applies to adults with type 2 diabetes and established cardiovascular disease, with the decision based on SURPASS-CVOT trial results.

Health Canada approved Eli Lilly and Company’s Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events among adults with type 2 diabetes and established cardiovascular disease.

Results from the SURPASS-CVOT trial formed the basis for the approval.


